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Abstract
The malarial parasite has a tremendous requirement for fatty acids during the replicative stages that
take place in the mammalian host. A series of recent papers, discussed below, have revealed some of
the mechanisms employed by the parasite to meet these demands.
Introduction and context
Upon infection of the mammalian host, malarial
parasites complete a phase of development and multi-
plication in hepatocytes prior to initiating infection of
erythrocytes. Given the high availability of nutrients in
both of these environments, early investigators postu-
lated that fatty acids required for the generation of
progeny parasites might be scavenged entirely from the
host.
Indeed, biochemical studies on blood-stage Plasmodium
malarial parasites first demonstrated the parasite’s
proficiency at scavenging and modifying lipids obtained
from the host [1]. Free fatty acids can beobtained directly
from the serum or from sources such as high-density
lipoprotein [2-5]. Within the parasite, scavenged phos-
pholipids can be incorporated without modification
[3,4]. Additionally, Plasmodium parasites can modify
fatty acids as needed by elongating or desaturating the
lipids and incorporating them into phospholipids, di-
acylglycerols and tri-acylglycerols [6,7]. The minimal
lipid requirement of blood-stage Plasmodium parasites
was determined to be a combination of palmitic acid and
oleic or steric acid, which could fully replace the need for
serum in culture [6,8].
Such biochemical analysis has not been possible for
liver-stage parasites because of the difficulty in isolating
the parasite from the host hepatocyte and the low rate of
infection during this stage. However, early studies of
malaria in genetically obese Zucker rats (fa/fa) gave the
first indication that host cell lipids are important for
Plasmodium liver-stage development [9]. These studies
demonstrated that obese Zucker rats, which have
hepatocytes with increased fatty acid synthesis, triglyceri-
demia, and triglyceride content, supported the growth of
four times the number of liver-stage schizonts than their
leaner counterparts. Additionally, 45 hours after infec-
tion, schizonts in the obese rats were twice the size of
those in control mice.
While it is not surprising that Plasmodium parasites
depend on host sources of fatty acids, the role of de novo
fatty acid synthesis in generating lipids remained
controversial until the discovery of the apicoplast
[10,11]. The apicoplast is a non-photosynthetic plastid
organelle that was likely derived from a secondary
endosymbiotic event during Apicomplexan evolution.
Analysis of the P. falciparum genome revealed the
presence of the apicoplast-resident biosynthetic fatty
acid synthesis type II (FAS-II) pathway, which is involved
in de novo synthesis of fatty acids [12,13]. The FAS-II
pathway is responsible for the elongation of fatty acids
via the action of four distinct enzymes: FabG, FabZ, FabI,
and FabB/F. The main precursor for this pathway is
acetyl-CoA, which is converted from pyruvate via the
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apicoplast [14]. In vitro studies reconstituting the FAS-II
pathway of Plasmodium provided evidence that Plasmo-
dium FAS-II enzymes predominantly generate C10-C14
fatty acids [15]. Clinical in vivo transcriptional data on
blood-stage parasites suggest that the FAS-II pathway can
be upregulated during conditions of starvation [16].
However, aside from this auxiliary function in times of
stress, the contribution of the FAS-II pathway during
blood-stage development appears to be minimal. FAS-II
enzymes are transcribed at a very low level in blood-stage
parasites [17]. Furthermore, blood-stage growth rates are
not impaired by deletion of fabI (in the human pathogen
P. falciparum or the virulent rodent model parasite
P. berghei), fabB/F, fabZ, or PDH subunits pdh-e1a or
pdh-e3 (in the less virulent rodent parasite, P. yoelii strain
17XNL) [18-20].
Major recent advances
Recent evidence suggests that the liver stage of parasite
development, in contrast with the blood stage, requires
a functional FAS-II pathway. This was initially suggested
by the relatively high expression of FAS-II genes during
this stage [21]. Conclusive evidence supporting a role
for de novo fatty acid synthesis in the liver was provided
by the observation that ΔfabI (in P. berghei), ΔfabZ,
ΔfabB/F, Δpdh-e1a,a n dΔpdh-e3 (in P. yoelii) parasites
exhibited deficiencies late in liver-stage development.
This included a slow rate of growth, abnormal nuclear
division, lack of cytomere formation, and lack of
expression of late-stage proteins such as merozoite
surface protein-1 (MSP-1) [18-20]. MSP-1 is a glycosyl-
phosphatidylinositol (GPI)-anchored protein present
on the plasma membrane of merozoites, the progeny
parasites that develop during the liver stage. Because
merozoites are required to initiate blood-stage infec-
tion, it was expected that FAS-II-deficient parasites
might not progress from liver to blood stage. Indeed,
P. yoelii ΔfabB/F, ΔfabZ, Δpdh-e1a,a n dΔpdh-e3 liver-
stage parasites were fully attenuated in their ability to
produce a blood-stage infection in mice. P. berghei ΔfabI
parasites exhibited a prepatent period that was twice
that of wild-type parasites. Nevertheless, these did
eventually lead to blood-stage infection. These differ-
ences in attenuation may be due to differences in
virulence between the two species, which might permit
clearance of low numbers of blood-stage forms of the
less virulent P. yoelii parasites by the host immune
response.
A screen of host cell proteins that might facilitate lipid
scavenging by the parasite during the liver stage has
pointed toward the surface-expressed cholesterol ester
receptor, scavenger receptor class B type 1 (SR-BI) [22].
A decrease or complete loss of SR-BI surface availability
via treatment with siRNA (short interfering RNA),
antibodies, drugs, or gene deletion results in a reduction
in parasite invasion and growth in hepatocytes [22,23].
The role of SR-BI expression in invasion and growth was
shown to be multifactorial. SR-BI expression results in
increased cell cholesterol levels. Together, SR-BI and
cholesterol work synergistically to increase cell surface
levels of CD81, particularly at tetraspanin-enriched
microdomains [23,24]. This localization of CD81 at
tetraspanin-enriched microdomains facilitates invasion
by P. yoelii and P. falciparum sporozoites [23-25]. In
addition,SR-BIexpressionresultsinupregulatedliverfatty
acid-binding protein (L-FABP) expression [23]. L-FABP is
a liver-specific cytosolic fatty acid-binding protein respon-
sible for transporting fatty acids. Presumably, L-FABP
delivershostcelllipidstothe growingparasite,supporting
the metabolic needs of the rapidly growing parasite. The
discovery that L-FABP binds the Plasmodium parasite
protein UIS3 supports this hypothesis [25,26]. UIS3 is
an essential liver-stage-specific parasite protein that is
localized at the parasitophorous vacuole, a phospholipid
bilayer interface that separates the parasite and the host
cell [26,27]. The ability of UIS3 to co-crystallize with
phosphatidylethanolamine suggests that UIS3 may coop-
erate with L-FABP to obtain phospholipids from the host
cell [28].
Future directions
Many questions remain to be answered with regard to
fatty acid metabolism in the Plasmodium liver stage.
Identification of the fatty acids synthesized during the
liver stage will provide insight into the minimal require-
ments for development during this stage. In addition, an
understanding of the respective contribution of the
scavenging and de novo synthesis pathways in parasite
growth would facilitate the development of better
strategies targeting the parasite during this stage.
While most scavenged and synthesized lipids are likely
incorporated into the membranes of the rapidly growing
parasite, additional roles for fatty acids remain to be
elucidated. For example, studies have yet to identify the
source of fatty acids that are incorporated into GPI, which
anchors numerous proteins, including MSP-1, to the
merozoite plasma membrane. The low expression of
MSP-1 in fab knockout parasites suggests that the FAS-II
pathway may act together with elongases and desaturases
to generate the lipid anchor for some surface proteins,
including MSP-1 [29]. Alternatively, the FAS-II pathway
activity may provide a signal for progression to the
merozoite formation phase of intrahepatic development.
The specific upregulation ofthe FAS-IIpathway during the
liver stage may allow the parasite to synthesize its own
Page 2 of 4
(page number not for citation purposes)
f1000 Biology Reports 2010, 2:24 http://f1000.com/reports/biology/content/2/24lipids to supplement those provided by the host
hepatocyte during a particularly explosive period of
growth in the Plasmodium life cycle. This notion is
supported by the decrease in growth rate of fabI, fabB/F,
fabZ, pdh-e1a,a n dpdh-e3 knockout parasites in the liver.
However, the parasite’s ability to multiply efficiently in
the mosquito host suggests that the FAS-II pathway
may be involved in processes unique to hepatic-stage
development.
With respect to lipid scavenging, the mechanism of lipid
import following association with UIS3 must be further
examined. Presumably, parasite-encoded proteins that
associate with UIS3 facilitate lipid incorporation into the
membrane of the parasitophorous vacuole. However, the
mechanisms of lipid import into the parasite remain
unknown. Plasmodium fatty acid-binding proteins have
not been characterized. A family of acyl-CoA synthetase
homologues present in the P. falciparum genome may
serve this function.
Both the lipid scavenging and lipid synthesis pathways
offer opportunities for the development of antimalarials.
Small molecules that interfere with the interaction of
UIS3 with either L-FABP or phospholipids may abrogate
infection in the liver. Genetically attenuated parasites
deficient in de novo synthesis of fatty acids via FAS-II gene
deletion, and rendered unable to import fatty acids from
the host hepatocyte, may serve as effective pre-erythrocytic-
stage whole-cell vaccines, analogous to the idea of using
genetically attenuated sporozoite vaccines. Both strategies
could protect the hostfrom the debilitating symptoms that
can arise following successful production of merozoites
in the liver. Elucidating stage-specific requirements for
import, synthesis, and utilization of fatty acids and lipids
in malarial parasites is both of considerable promise for
developing novel antimalarial intervention strategies and
of fundamental interest in understanding how these
parasites are so successful in establishing infection in the
human host.
Abbreviations
FAS-II, fatty acid synthesis type II; GPI, glycosylpho-
sphatidylinositol; L-FABP, liver fatty acid-binding pro-
tein; MSP-1, merozoite surface protein-1; PDH, pyruvate
dehydrogenase; SR-BI, scavenger receptor class B type 1.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
Funding for this work was provided in part by a
transformative R01 (AI085584) from the National
Institutes of Health to DAF.
References
1. Vial HJ, Thuet MJ, Philippot JR: Phospholipid biosynthesis in
synchronous Plasmodium falciparum cultures. J Protozool 1982,
29:258-63.
2. Grellier P, Rigomier D, Clavey V, Fruchart JC, Schrevel J: Lipid
traffic between high density lipoproteins and Plasmodium
falciparum-infected red blood cells. J Cell Biol 1991, 112:267-77.
3. Krishnegowda G, Gowda DC: Intraerythrocytic Plasmodium
falciparum incorporates extraneous fatty acids to its lipids
without any structural modification. Mol Biochem Parasitol 2003,
132:55-8.
4. Moll GN, Vial HJ, Ancelin ML, Op den Kamp JAF, Roelofsen B,
van Deenen LLM: Phospholipid uptake by Plasmodium knowlesi
infected erythrocytes. FEBS Letters 1988, 232:341-6.
5. Ofulla AV, Okoye VC, Khan B, Githure JI, Roberts CR, Johnson AJ,
Martin SK: Cultivation of Plasmodium falciparum parasites in a
serum-free medium. Am J Trop Med Hyg 1993, 49:335-40.
6. Mi-Ichi F, Kita K, Mitamura T: Intraerythrocytic Plasmodium
falciparum utilize a broad range of serum-derived fatty acids
with limited modification for their growth. Parasitology 2006,
133:399-410.
7. Palacpac NMQ, Hiramine Y, Mi-ichi F, Torii M, Kita K, Hiramatsu R,
Horii T, Mitamura T: Developmental-stage-specific triacylgly-
cerol biosynthesis, degradation and trafficking as lipid bodies
in Plasmodium falciparum-infected erythrocytes. J Cell Sci 2004,
117:1469-80.
8. Mi-Ichi F, Kano S, Mitamura T: Oleic acid is indispensable for
intraerythrocytic proliferation of Plasmodium falciparum.
Parasitology 2007, 134:1671-7.
9. Lombard M-N, Bazin R, Durand D, Beauge F, Baccam D, Milgen F,
Landau I: Rodent Plasmodium development in livers of
genetically obese Zucker rats (fa/fa). Eur J Protistol 1998,
34:78-81.
10. Kohler S, Delwiche CF, Denny PW, Tilney LG, Webster P,
Wilson RJM, Palmer JD, Roos DS: A plastid of probable green
a l g a lo r i g i ni nA p i c o m p l e x a np a r a s i t e s .Science 1997,
275:1485-9.
11. McFadden GI, Reith ME, Munholland J, Lang-Unnasch N: Plastid in
human parasites. Nature 1996, 381:482.
12. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW,
Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K,
Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S,
Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J,
Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, et al.:
Genome sequence of the human malaria parasite Plasmodium
falciparum. Nature 2002, 419:498-511.
f1000 Factor 6.0 Must Read
Evaluated by Carol Sibley 16 Oct 2002
13. Ralph SA, van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ,
Foth BJ, Tonkin CJ, Roos DS, McFadden GI: Tropical infectious
diseases: metabolic maps and functions of the Plasmodium
falciparum apicoplast. Nat Rev Microbiol 2004, 2:203-16.
14. Foth B, Stimmler LM, Handman E, Crabb B, Hodder AN, McFadden G:
The malaria parasite Plasmodium falciparum has only one
pyruvate dehydrogenase complex, which is located in the
apicoplast. Mol Microbiol 2005, 55:39-53.
f1000 Factor 6.0 Must Read
Evaluated by Jurgen Soll 19 Jan 2005
15. Sharma S, Sharma SK, Modak R, Karmodiya K, Surolia N, Surolia A:
Mass spectrometry-based systems approach for identification
of inhibitors of Plasmodium falciparum fatty acid synthase.
Antimicrob Agents Chemother 2007, 51:2552-8.
16. Daily JP, Scanfeld D, Pochet N, Le Roch K, Plouffe D, Kamal M,
Sarr O, Mboup S, Ndir O, Wypij D, Levasseur K, Thomas E,
Tamayo P, Dong C, Zhou Y, Lander ES, Ndiaye D, Wirth D,
Winzeler EA, Mesirov JP, Regev A: Distinct physiological states of
Page 3 of 4
(page number not for citation purposes)
f1000 Biology Reports 2010, 2:24 http://f1000.com/reports/biology/content/2/24Plasmodium falciparum in malaria-infected patients. Nature
2007, 450:1091-5.
f1000 Factor 9.0 Exceptional
Evaluated by Roberto Docampo 04 Jan 2008
17. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL: The
transcriptome of the intraerythrocytic developmental cycle
of Plasmodium falciparum. PLoS Biol 2003, 1:e5.
f1000 Factor 9.0 Exceptional
Evaluated by Emanuela Handman 20 Jan 2004
18. Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ,
Moura PA, Lakshmanan V, Freundlich JS, Valderramos JC, Vilcheze C,
Siedner M, Tsai JH, Falkard B, Sidhu AB, Purcell L, Gratraud P,
Kremer L, Waters A, Schiehser G, Jacobus DP, Janse C, Ager A,
Jacobs WR, Sacchettini JC, Heussler V, Sinnis P, Fidock DA: The fatty
acid biosynthesis enzyme FabI plays a key role in the
development of liver-stage malarial parasites. Cell Host Microbe
2008, 4:567-78.
f1000 Factor 6.4 Must Read
Evaluated by Frank Seeber 14 Jan 2009, Matthew Bogyo 12 Nov
2009
19. Vaughan AM, O’Neill MT, Tarun AS, Camargo N, Phuong TM, Aly ASI,
Cowman AF, Kappe SHI: Type II fatty acid synthesis is essential
only for malaria parasite late liver stage development. Cell
Microbiol 2009, 11:506-20.
20. Pei Y, Tarun AS, Vaughan AM, Herman RW, Soliman JMB, Erickson-
Wayman A, Kappe SH: Plasmodium pyruvate dehydrogenase
activity is only essential for the parasite’s progression from
liver infection to blood infection. Mol Microbiol 2010, [Epub ahead
of print].
21. Tarun AS, Peng X, Dumpit RF, Ogata Y, Silva-Rivera H, Camargo N,
Daly TM, Bergman LW, Kappe SH: A combined transcriptome
and proteome survey of malaria parasite liver stages. Proc Natl
Acad Sci U S A 2008, 105:305-10.
f1000 Factor 6.0 Must Read
Evaluated by Paul Roepe 10 Jan 2008
22. Rodrigues CD, Hannus M, Prudencio M, Martin C, Goncalves LA,
Portugal S, Epiphanio S, Akinc A, Hadwiger P, Jahn-Hofmann K, Rohl I,
van Gemert GJ, Franetich J, Luty AJ, Sauerwein R, Mazier D,
Koteliansky V, Vornlocher HP, Echeverri CJ, Mota MM: Host
scavenger receptor SR-BI plays a dual role in the establish-
ment of malaria parasite liver infection. Cell Host Microbe 2008,
4:271-82.
23. Yalaoui S, Huby T, Franetich J, Gego A, Rametti A, Moreau M,
Collet X, Siau A, van Gemert GJ, Sauerwein RW, Luty AJ, Vaillant JC,
Hannoun L, Chapman J, Mazier D, Froissard P: Scavenger receptor
BI boosts hepatocyte permissiveness to Plasmodium infection.
Cell Host Microbe 2008, 4:283-92.
24. Silvie O, Charrin S, Billard M, Franetich J-F, Clark KL, van Gemert G-J,
Sauerwein RW, Dautry F, Boucheix C, Mazier D, Rubinstein E:
Cholesterol contributes to the organization of tetraspanin-
enriched microdomains and to CD81-dependent infection by
malaria sporozoites. J Cell Sci 2006, 119:1992-2002.
25. Silvie O, Rubinstein E, Franetich J, Prenant M, Belnoue E, Renia L,
Hannoun L, Eling W, Levy S, Boucheix C, Mazier D: Hepatocyte
CD81 is required for Plasmodium falciparum and Plasmodium
yoelii sporozoite infectivity. Nat Med 2003, 9:93-6.
f1000 Factor 6.0 Must Read
Evaluated by Dominique Soldati 14 Jan 2003
26. Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Camargo N,
Kappe SH: L-FABP is a critical host factor for successful
malaria liver stage development. Int J Parasitol 2007, 37:483-9.
27. Mueller AK, Labaied M, Kappe SH, Matuschewski K: Genetically
modified Plasmodium parasites as a protective experimental
malaria vaccine. Nature 2005, 433:164-7.
f1000 Factor 8.3 Exceptional
Evaluated by Rino Rappuoli 21 Jan 2005, Ulf Pettersson 24 Jan 2005,
Stefan Kaufmann 01 Feb 2005, Ricardo Gazzinelli 15 Feb 2005
28. Sharma A, Yogavel M, Akhouri RR, Gill J, Sharma A: Crystal
structure of soluble domain of malaria sporozoite protein
UIS3 in complex with lipid. J Biol Chem 2008, 283:24077-88.
f1000 Factor 3.0 Recommended
Evaluated by Rajesh Gokhale 23 Jul 2008
29. Gratraud P, Huws E, Falkard B, Adjalley S, Fidock DA, Berry L,
Jacobs WR, Baird MS, Vial H, Kremer L: Oleic acid biosynthesis in
Plasmodium falciparum: characterization of the stearoyl-CoA
desaturase and investigation as a potential therapeutic
target. PLoS ONE 2009, 4:e6889.
Page 4 of 4
(page number not for citation purposes)
f1000 Biology Reports 2010, 2:24 http://f1000.com/reports/biology/content/2/24